Inhibrx Biosciences, Inc.
INBX
$12.33
$0.181.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 200.00K | 1.73M | 1.85M | 1.78M | 1.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 200.00K | 1.73M | 1.85M | 1.78M | 1.80M |
| Cost of Revenue | 203.74M | 252.47M | 251.63M | 218.11M | 191.64M |
| Gross Profit | -203.54M | -250.73M | -249.78M | -216.32M | -189.84M |
| SG&A Expenses | 59.84M | 119.04M | 119.03M | 32.92M | 29.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 263.59M | 371.51M | 370.66M | 251.03M | 220.99M |
| Operating Income | -263.39M | -369.77M | -368.80M | -249.24M | -219.19M |
| Income Before Tax | 1.69B | 1.64B | 1.63B | -271.15M | -241.36M |
| Income Tax Expenses | 2.00K | -2.00K | 0.00 | 3.00K | 3.00K |
| Earnings from Continuing Operations | 1.69K | 1.64K | 1.63K | -271.16 | -241.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.69B | 1.64B | 1.63B | -271.16M | -241.36M |
| EBIT | -263.39M | -369.77M | -368.80M | -249.24M | -219.19M |
| EBITDA | -261.10M | -367.88M | -367.37M | -247.99M | -217.99M |
| EPS Basic | 115.39 | 111.57 | 110.01 | -21.40 | -20.12 |
| Normalized Basic EPS | -11.55 | -16.69 | -17.66 | -13.37 | -12.57 |
| EPS Diluted | 113.77 | 109.95 | 108.40 | -21.40 | -20.12 |
| Normalized Diluted EPS | -11.46 | -16.60 | -17.58 | -13.37 | -12.57 |
| Average Basic Shares Outstanding | 59.19M | 57.26M | 53.58M | 49.87M | 47.12M |
| Average Diluted Shares Outstanding | 59.38M | 57.44M | 53.76M | 49.87M | 47.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |